Escitalopram Pregnancy and Breastfeeding Warnings
Escitalopram is also known as: Lexapro
Escitalopram Pregnancy Warnings
Escitalopram has been assigned to pregnancy category C by the FDA. Escitalopram is the S-enantiomer of racemic citalopram. Human spontaneous abortion has been reported by the manufacturer of citalopram. Animal studies have revealed evidence of adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses. There are no controlled data in human pregnancy. Escitalopram should be given during pregnancy only if the potential benefit outweighs the potential risk to the fetus.
Escitalopram Breastfeeding Warnings
In one case, the infant was reported to have recovered completely upon discontinuation of citalopram by the mother. In the second case, no follow up information is available.
Racemic citalopram is excreted into human milk. There have been two reports of infants experiencing excess somnolence, decreased feeding, and weight loss in association with breast-feeding from a citalopram- treated mother. The decision to continue or discontinue either nursing or escitalopram therapy should take into account both the risks of escitalopram exposure to the infant and the benefits of escitalopram therapy for the mother. The results of two case reports and a small study appear to indicate that escitalopram has a low potential for causing adverse effects in breastfed infants. In the study, mothers (n=8) received a median escitalopram dose of 10 mg daily (range 10 to 20 mg). At steady state, the mean milk/plasma ratio for escitalopram and demethylescitalopram were both 2.2 and the absolute infant doses were 7.6 mcg/kg/day and 3.0 mcg/kg/day, respectively. The overall mean relative infant dose for escitalopram and demethylescitalopram was 5.3% of the weight- adjusted maternal dose. Compared with maternal plasma levels, plasma levels of parent drug and metabolite in the infants tested were low or below the limit of detection. Assessment of all of the breastfed infants (i.e., case reports and study) revealed no adverse effects.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.